Argy is pleased to announce the addition of John Harder, as Partner in the Business Consulting Group. Based out of our headquarters in McLean, VA, John will assist clients in the areas of process improvement, technology risk and technology assessment and implementation.
Did you know that states are considering phasing out their current taxing schemes? Did you know that other states are updating their nexus standards with respect to subjecting "foreign" corporations to taxation? Did you know that state legislatures are attempting to revise their apportionment factors? As states continue to deal with shortfalls in their respective budgets, many are considering some of these options.
The economic downturn has forced many companies to look for ways to increase revenues or decrease costs. For the biotech industry, such economic conditions create additional risk and have a major impact on a company's ability to obtain venture capital, initiate public stock offerings, and secure loans due to its high-risk/high-reward nature. Many biotechnology companies have looked at the Federal Government as a source of additional funding to supplement the other sources of funding.
Our firm provides the information in this e-newsletter for general guidance only, and does not constitute the provision of legal advice, tax advice, accounting services, investment advice, or professional consulting of any kind. The information provided herein should not be used as a substitute for consultation with professional tax, accounting, legal, or other competent advisers. Before making any decision or taking any action, you should consult a professional adviser who has been provided with all pertinent facts relevant to your particular situation. Tax articles in this e-newsletter are not intended to be used, and cannot be used by any taxpayer, for the purpose of avoiding accuracy-related penalties that may be imposed on the taxpayer. The information is provided "as is," with no assurance or guarantee of completeness, accuracy, or timeliness of the information, and without warranty of any kind, express or implied, including but not limited to warranties of performance, merchantability, and fitness for a particular purpose.
IRS Circular 230 Disclosure: Please be advised that the tax advice contained herein (including any attachments) is not intended or written by the practitioner to be used and cannot be used by the taxpayer for the purpose of avoiding any U.S. tax-related penalties that may be imposed on the taxpayer.
Argy is pleased to announce the addition of John Harder, as Partner in the Business Consulting Group. Based out of our headquarters in McLean, VA, John will assist clients in the areas of process improvement, technology risk and technology assessment and implementation.
The economic downturn has forced many companies to look for ways to increase revenues or decrease costs. For the biotech industry, such economic conditions create additional risk and have a major impact on a company's ability to obtain venture capital, initiate public stock offerings, and secure loans due to its high-risk/high-reward nature. Many biotechnology companies have looked at the Federal Government as a source of additional funding to supplement the other sources of funding.
Consider this scenario: An employee files a discrimination charge against a company. A short time later, the company fires another employee who is close to the individual making the discrimination claim. Has the company retaliated against the second employee? This question was answered in a recent Supreme Court case. Here are the details of the ruling, along with the basics of retaliation and recent EEOC cases.
When you back a startup, make sure the new company is structured in a way that gives you profits if the venture succeeds and write-offs if it fails. Here's a smart two-part plan.
Employee duties and how well they are performed are directly linked to your company's profits. But staff members aren't always clear on how their jobs translate into a healthy bottom line. Click "Full Article for some tips to help them see more clearly how important they are.
Let's say you receive a tip that someone inside your company is stealing. An investigation is launched and there is evidence of fraud. But important details of the investigation are mishandled, which results in the company losing out on the opportunity to recoup losses, prosecute those involved, and set an ethical tone. To help ensure a successful outcome, here are six costly mistakes to avoid when investigating internal fraud.
